Lupin strengthens biological products pipeline

02 Jun 2011 Evaluate

The company has entered into licensing agreement with Sydney-based NeuClone Pty Ltd for cell-line technology. A private specialty life-science company, NeuClone will provide the exclusive proprietary cell-line technology to be developed into bio-similar drugs targeting cancer. Biologicals are drugs made in cells and bio-generics are products similar to innovative biological medicine.

With about six to eight proteins in its pipeline, Lupin is looking to develop these biological products keeping an eye on the still-evolving regulatory framework in developed markets such as the US, European Union and Japan.

Having entered the biotech space about three years ago, Lupin expects 5 to 7 per cent of its business to come from the bio-similars business, in about five years. The company expects to have its first bio-similar product in the Indian market by early next year. It has a separate research facility in Pune, with about 100 scientists, focused on biotech.

Industry estimates the global market for bio-similars or follow-on biologic drugs at about $100 billion. The Indian market for biosimilar products, such as insulin, hormones, vaccines and plasma proteins, is about Rs 2,500 crore.

crackcrack

Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.